Yazar "Urakci, Z." seçeneğine göre listele
Listeleniyor 1 - 10 / 10
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Comparision of Radiotheraphy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer(Elsevier Science Inc, 2018) Akdeniz, N.; Kaplan, M. A.; Urakci, Z.; Kucukoner, M.; Karhan, O.; Isikdogan, A.[Abstract Not Available]Öğe Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer(Oxford Univ Press, 2019) Isikogan, A.; Akdeniz, N.; Kucukoner, M.; Kaplan, M. A.; Urakci, Z.; Karhan, O.; Sezgin, Y.[Abstract Not Available]Öğe Comparison of three different docetaxel and cisplatin plus fluorouracil (DCF) as first-line therapy for advanced gastric cancer: A retrospective analysis of the two institution(Elsevier Sci Ltd, 2013) Inal, A.; Koca, D.; Kaplan, M. A.; Kucukoner, M.; Urakci, Z.; Dogan, E.; Isikdogan, A.[Abstract Not Available]Öğe CRANIAL MAGNETIC RESONANCE IMAGING (MRI) IN THE STAGING OF HER2-POSITIVE BREAST CANCER PATIENTS(Oxford Univ Press, 2012) Kaplan, M. A.; Inal, A.; Kucukoner, M.; Urakci, Z.; Ekici, F.; Firat, U.; Isikdogan, A.[Abstract Not Available]Öğe Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials(Elsevier, 2022) Ergun, Y.; Kalkan, Z.; Ileri, S.; Tunc, S.; Urakci, Z.[Abstract Not Available]Öğe Efficacy of recombinant FVIIA treatment in inhibitor positive hemophilic patients and in Glanzmann thrombasthenia: Single center experience(Ferrata Storti Foundation, 2007) Altintas, A.; Pasa, S.; Urakci, Z.; Muftuoglu, O. E.; Cil, T.[Abstract Not Available]Öğe Is 18F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience(Elsevier Espana Slu, 2013) Inal, A.; Kucukoner, M.; Kaplan, M. A.; Urakci, Z.; Nas, N.; Guven, M.; Dostbil, Z.Background: Although a number of studies in patients with a variety of malignant tumors have shown that metabolic activity on fluorine-18 deoxyglucose positron emission tomography computed tomography (F-18-FDG-PET/CT) is correlated with survival, there are few studies about the impact of F-18-FDG-PET/CT for survival in small cell lung cancer (SCLC) patients. There is still some ambiguity as to whether FDG PET in patients with SCLC will ensure prognostic knowledge for survival. We performed a retrospective analysis of prognostic implication of F-18-FDG-PET/CT in patients with SCLC. Methods: We retrospectively reviewed 54 patients with histologically or cytologically proven SCLC who had undergone pre-treatment F-18-FDG-PET/CT scanning between September 2007 and November 2011 in the Dicle University, School of Medicine, Department of Medical Oncology. SUVmax and other potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: Among the eleven variables of univariate analysis, three variables were identified as having prognostic significance: Performance status (p < 0.001), stage (p = 0.02) and diabetes mellitus (p =0.05). Multivariate analysis showed that performance status and stage were considered independent prognostic factors for survival (p< 0.001 and p- 0.002 respectively). Conclusion: In conclusion, performance status and stage were identified as important prognostic factors, while F-18-FDG-PET/CT uptake of the primary lesions was not associated with prognostic importance for survival in patients with SCLC. (C) 2012 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L. All rights reserved.Öğe Is Cranial Magnetic Resonance Imaging (MRI) Necessary for Staging of Asymptomatic HER2-Positive Breast Cancer Patients?(Amer Assoc Cancer Research, 2011) Kaplan, M. A.; Inai, A.; Kucukoner, M.; Urakci, Z.; Isikdogan, A.[Abstract Not Available]Öğe Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with advanced non-small cell lung cancer: Single center experience(Imprimatur Publications, 2012) Inal, A.; Kucukoner, M.; Kaplan, M. A.; Urakci, Z.; Karakus, A.; Komek, H.; Dostbil, Z.Purpose: The purpose of this retrospective single-center study was to evaluate the prognostic implication on overall survival (OS) of the F-18 FDG PET scan in locally advanced or metastatic non small cell lung cancer (NSCLC) patients. Methods: We retrospectively reviewed 120 locally advanced or metastatic NSCLC patients (December 2004-November 2011) treated/followed at the Dicle University, School of Medicine, Department of Medical Oncology. SUVmax and other potential prognostic variables (n=18) were chosen for analysis. Univariate and multivariate analyses were conducted to identify prognostic factors for OS. Results: Among 18 variables of univariate analysis, 6 were identified to bear prognostic significance: sex (p=0.01), performance status (PS) (p=0.03), stage (p=0.04), bone metastases (p=0.002), serum albumin (p=0.01) and blood glucose level (p=0.03). Multivariate analysis showed that PS, bone metastases and serum albumin level were independent prognostic factors for OS (p=0.01, p=0.004, p=0.003, respectively). Conclusion: PS, serum albumin levels and bone metastases were independent prognostic factors, while FDG uptake of the primary lesion was not associated with prognosis of OS in locally advanced or metastatic NSCLC patients.Öğe The Role of Serum Carcinoembryonic Antigen to Predict the Response of Treatment in Non-Small Cell Lung Cancer Patients(Elsevier Science Inc, 2018) Akdeniz, N.; Kaplan, M. A.; Kucukoner, M.; Urakci, Z.; Karhan, O.; Isikdogan, A.[Abstract Not Available]
